SB35 (ixekizumab biosimilar)
/ Samsung
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 15, 2026
A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants
(clinicaltrials.gov)
- P1 | N=174 | Recruiting | Sponsor: Samsung Bioepis Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open
August 28, 2026
A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants
(clinicaltrials.gov)
- P1 | N=174 | Not yet recruiting | Sponsor: Samsung Bioepis Co., Ltd.
New P1 trial
1 to 2
Of
2
Go to page
1